Physician profile
Guy C Arnall
NPI 1760464341
$2,776.62
in general payments reported to CMS, 2019-2025
36 companies · $589 in 2025
The $589 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $191 · 2021: $14.87 · 2022: $381 · 2023: $64.90 · 2024: $618 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $247.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $245.80 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $232.20 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $215.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Radius Health, INC. | $185.27 | 2019 | |
| Novo Nordisk INC | $184.86 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.31 | 2019-2024 | Jardiance, Synjardy |
| Sumitomo Pharma America, INC. | $120.23 | 2024-2025 | Gemtesa |
| Abbvie INC. | $114.36 | 2019-2024 | Vraylar |
| Sanofi-Aventis U.S. LLC | $104.29 | 2019-2020 | |
| Astellas Pharma US INC | $98.48 | 2019-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $85.21 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $84.36 | 2024-2025 | Auvelity |
| Avanos Medical | $82.74 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.84 | 2020-2025 | Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $76.41 | 2019-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $51.67 | 2019-2020 | |
| Bausch Health US, LLC | $42.97 | 2024-2025 | Wellbutrin, Aplenzin |
| Dexcom, INC. | $38.96 | 2023-2025 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $37.18 | 2020-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $37.15 | 2022 | |
| Sunovion Pharmaceuticals INC. | $34.39 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.47 | 2022 | |
| Merck Sharp & Dohme LLC | $28.32 | 2019-2020 | |
| Genentech USA, INC. | $24.25 | 2019 | |
| Shire North American Group INC | $23.16 | 2019 | |
| Neos Therapeutics, Lp | $18.71 | 2019 | |
| Amarin Pharma, INC. | $16.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.17 | 2019 | |
| Dynavax Technologies Corporation | $16.01 | 2025 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $15.27 | 2022 | |
| Antares Pharma, INC. | $15.13 | 2019 | |
| Allergan, INC. | $12.79 | 2019 | |
| Circassia INC. | $12.34 | 2019 | |
| Mannkind Corporation | $11.18 | 2019 | |
| Companion Medical, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Arnall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.